KEYNOTE-427 (Cohort A): Phase II Study of Pembrolizumab Monotherapy for First-line Treatment of Patients With Advanced Clear-Cell Renal Cell Carcinoma

June 1-5, 2018; Chicago, Illinois
Pembrolizumab active in the first-line setting for patients with advanced ccRCC with no unexpected toxicities.
Format: Microsoft PowerPoint (.ppt)
File Size: 194 KB
Released: June 6, 2018


Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Celgene Corporation
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Daniel P. Petrylak, MD, and Elizabeth R. Plimack, MD, MS, review key data in genitourinary cancers from the 2021 ASCO Annual Meeting, as reported by Clinical Care Options (CCO)

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 7, 2021 Expired: September 6, 2022

Global perspectives of key novel combination studies presented at ASCO 2021 from international experts in solid tumors from Clinical Care Options (CCO)

Dirk Arnold, MD, PhD Prof Isabelle Ray-Coquard, MD, PhD Egbert F. Smit, MD, PhD Released: August 5, 2021

Download slides on selected studies of combination therapy approaches in solid tumors, from ASCO 2021 as reported by Clinical Care Options (CCO).

Released: June 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.